Investing.com -- Maze Therapeutics Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.
Maze's lead drug candidate, MZE829, is an oral APOL1 inhibitor being developed for APOL1-mediated kidney disease.
Analysts expect key Phase II HORIZON trial data in early 2026, with TD Cowen highlighting its potential to address over 1 million AKD patients and noting its potency advantage over Vertex's (NASDAQ:VRTX) inaxaplin.
Guggenheim sees Maze as a compelling investment, given the estimated $10 billion to $15 billion market opportunity in APOL1-associated kidney disease.
Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it as a first-in-class therapy with significant commercial potential.
JPMorgan, which set a $30 price target, sees multiple catalysts for Maze, emphasizing the breadth of MZE829’s potential patient base and its differentiation from Vertex’s drug. Guggenheim set a $19 price target, citing value-inflecting data expected over the next year.
Related Articles
Maze Therapeutics receives positive ratings following recent IPO
Intuit earnings beat by $0.74, revenue topped estimates
Workday earnings beat by $0.14, revenue topped estimates
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。